De-Novo Marketing FDA Approval for Natural Cycles’ Contraception App

August 14, 2018  Source: MobiHealthNews 174

"/

The US-FDA (US- Food and Drugs Administration) announced on 13 August that it will permit the marketing of Natural Cycles’ contraception app in the US for pre-menopausal women aged 18 years and older. This app was previously approved in the UK and is currently being investigated by various regulatory agencies. This algorithm-driven app helps in tracking menstrual cycles and informs users of their fertile status.

Dr. Terri Cornelison, the assistant director for the health of women in the FDA’s Center for Devices and Radiological Health, said “Consumers are increasingly using digital health technologies to inform their everyday health decisions, and this new app can provide an effective method of contraception if it’s used carefully and correctly; But women should know that no form of contraception works perfectly, so an unplanned pregnancy could still result from correct usage of this device.”

This contraception app is a subscription service which includes both the app and a basal thermometer. By taking the temperature in morning and submitting extra information about their cycle, the app generates details about the user’s fertility. The app is a CE certified contraceptive in Europe, which raised $30 million in funding in November 2017.

The low-to-moderate-risk levels of the app were reviewed through the FDA’s de novo premarket review pathway. The FDA announced that it would be launching “special control” criteria to shed light on its reliability, accuracy, and pregnancy prevention effectiveness for future contraception apps. But the investigations regarding robust substantiation and unplanned pregnancies while using the app are still ongoing.

By Ddu
Share: